Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800636 | 0.81 | TDP1 (0.34) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL12974511 | 0.79 | ALDH1A1 (0.31) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL10819618 | 0.78 | ECE1 (0.36) | ALDH1A1 | |
| SCHEMBL800722 | 0.77 | TDP1 (0.31) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL10819619 | 0.75 | ALOX15 (0.40) | ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL13295946 | 0.74 | MEN1 (0.38) | — | |
| SCHEMBL12277981 | 0.74 | ALOX15 (0.42) | — | |
| SCHEMBL10140886 | 0.73 | CYP2D6 (0.50) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL10136465 | 0.73 | KDM4E (0.40) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL12017871 | 0.73 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| EP-2968080-B1 | ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR | SYNEDGEN INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | SYNEDGEN, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11433092-B2 | Compositions and methods of use for wound healing | SYNEDGEN, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210386774-A1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK | SYNEDGEN, INC. | 2021-12-16 | — | — | US | disclosed |
| US-11077135-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | SYNEDGEN, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200299417-A1 | CHITOSAN-DERIVATIVE COMPOUNDS AND METHODS OF CONTROLLING MICROBIAL POPULATIONS | UNITED STATES GOVERNMENT | 2020-09-24 | — | — | US | disclosed |
| US-10765616-B2 | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar | SYNEDGEN, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10716803-B2 | Methods for treatment or prevention of damage resulting from radiation, trauma or shock | SYNEDGEN, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | SYNEDGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | SYNEDGEN INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010056927-A1 | CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20080194554-A1 | Hiv Protease Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194554-A1 | Hiv Protease Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433092-B2 | Compositions and methods of use for wound healing | PARG, ARGLU1, AREG | ALDH1A1 3165/4885LMNA 2017/4885MAPT 4258/4885 |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF18B, KIF5B, KIF18A | ALDH1A1 2246/4885LMNA 2708/4885MAPT 248/4885 |
| US-20210386774-A1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK | HMGB1, ELANE, SERPINB1 | ALDH1A1 2079/4885LMNA 843/4885MAPT 3121/4885 |
| US-20200299417-A1 | CHITOSAN-DERIVATIVE COMPOUNDS AND METHODS OF CONTROLLING MICROBIAL POPULATIONS | ARG1, NRDC, CHIA | ALDH1A1 3593/4885LMNA 1979/4885MAPT 3331/4885 |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | CHIT1, CHIA, ALG1 | ALDH1A1 3341/4885LMNA 1960/4885MAPT 3595/4885 |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | ALDH1A1 2214/4885LMNA 2512/4885MAPT 295/4885 |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | ARG1, ARG2, FUT6 | ALDH1A1 3377/4885LMNA 2156/4885MAPT 1671/4885 |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | ARG1, NRDC, CHIA | ALDH1A1 3593/4885LMNA 1979/4885MAPT 3331/4885 |
| US-20080194554-A1 | Hiv Protease Inhibitors | PREP, DNPEP, ANPEP | ALDH1A1 3895/4885LMNA 4110/4885MAPT 693/4885 |
| US-10716803-B2 | Methods for treatment or prevention of damage resulting from radiation, trauma or shock | HMGB1, ELANE, SERPINB1 | ALDH1A1 2079/4885LMNA 843/4885MAPT 3121/4885 |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | CHIA, MMP8, CHIT1 | ALDH1A1 2248/4885LMNA 1695/4885MAPT 4782/4885 |
| US-11077135-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | CHIA, CHI3L1, CHI3L2 | ALDH1A1 2896/4885LMNA 927/4885MAPT 1884/4885 |
| US-10765616-B2 | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar | FUT6, FUT5, PGLS | ALDH1A1 4166/4885LMNA 3204/4885MAPT 2745/4885 |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | CHIT1, CHIA, ALG1 | ALDH1A1 4191/4885LMNA 3640/4885MAPT 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.